249 related articles for article (PubMed ID: 12930690)
41. Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma.
Fitzgerald JC; Scherr AM; Barr FG
Cancer Genet Cytogenet; 2000 Feb; 117(1):37-40. PubMed ID: 10700864
[TBL] [Abstract][Full Text] [Related]
42. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
Barr FG; Smith LM; Lynch JC; Strzelecki D; Parham DM; Qualman SJ; Breitfeld PP
J Mol Diagn; 2006 May; 8(2):202-8. PubMed ID: 16645206
[TBL] [Abstract][Full Text] [Related]
43. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
[TBL] [Abstract][Full Text] [Related]
44. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
[TBL] [Abstract][Full Text] [Related]
45. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.
Rodeberg DA; Nuss RA; Heppelmann CJ; Celis E
Cancer Immunol Immunother; 2005 Jun; 54(6):526-34. PubMed ID: 15838707
[TBL] [Abstract][Full Text] [Related]
46. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma.
Kempf BE; Vogt PK
Cell Growth Differ; 1999 Dec; 10(12):813-8. PubMed ID: 10616906
[TBL] [Abstract][Full Text] [Related]
47. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR.
Begum S; Emami N; Cheung A; Wilkins O; Der S; Hamel PA
Oncogene; 2005 Mar; 24(11):1860-72. PubMed ID: 15688035
[TBL] [Abstract][Full Text] [Related]
48. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
49. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma.
Barr FG
Cancer Res; 1999 Apr; 59(7 Suppl):1711s-1715s. PubMed ID: 10197585
[TBL] [Abstract][Full Text] [Related]
50. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
Lam PY; Sublett JE; Hollenbach AD; Roussel MF
Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583
[TBL] [Abstract][Full Text] [Related]
51. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
[TBL] [Abstract][Full Text] [Related]
52. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein.
Ayalon D; Glaser T; Werner H
Growth Horm IGF Res; 2001 Oct; 11(5):289-97. PubMed ID: 11735247
[TBL] [Abstract][Full Text] [Related]
53. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.
Anderson MJ; Shelton GD; Cavenee WK; Arden KC
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1589-94. PubMed ID: 11171995
[TBL] [Abstract][Full Text] [Related]
54. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
Bennicelli JL; Edwards RH; Barr FG
Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
[TBL] [Abstract][Full Text] [Related]
55. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
56. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.
Lagutina I; Conway SJ; Sublett J; Grosveld GC
Mol Cell Biol; 2002 Oct; 22(20):7204-16. PubMed ID: 12242297
[TBL] [Abstract][Full Text] [Related]
57. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
Xia SJ; Barr FG
Oncogene; 2004 Sep; 23(41):6864-71. PubMed ID: 15286710
[TBL] [Abstract][Full Text] [Related]
58. Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic assay.
de Alava E; Ladanyi M; Rosai J; Gerald WL
Am J Pathol; 1995 Dec; 147(6):1584-91. PubMed ID: 7495283
[TBL] [Abstract][Full Text] [Related]
59. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
[TBL] [Abstract][Full Text] [Related]
60. Clinical relevance of molecular diagnosis in childhood rhabdomyosarcoma.
Tobar A; Avigad S; Zoldan M; Mor C; Goshen Y; Zaizov R
Diagn Mol Pathol; 2000 Mar; 9(1):9-13. PubMed ID: 10718207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
